<DOC>
	<DOCNO>NCT00196976</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity one dose four different formulation MenACWY conjugate vaccine give healthy child age 12-14 month 3-5 year . The selection best formulation base data obtain one month vaccine dose . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity 1 Dose GSK134612 Children 12-14 Months 3-5 Years Old</brief_title>
	<detailed_description>The study enrol subject 12 14 month age subject 3 5 year age . 3 formulation GSK 's MenACWY conjugate vaccine administer double-blind manner , 4th one single-blinded . Administration candidate vaccine active control ( MenC-CRM197 Mencevaxâ„¢ ACWY ) do open manner . The study conduct two stage : The primary vaccination phase ( Study Stage 1 ) study include subject ; second ( booster/persistence ) phase study ( Study Stage 2 ) include subject active control group group prim select MenACWY formulation . The study conduct double-blind manner group receive formulation A , B , C single blind manner respect group receive formulation D. The control vaccine administer open manner respect investigational vaccination regimen . Each group one blood sample prior one blood sample one month first vaccine dose .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include 12 14 month 3 5 year age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her parents'/guardians ' knowledge . For pertussis vaccination , child age 1214 month vaccinate acellular pertussis vaccine . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month first dose vaccine one month administration study vaccine dose exception oral polio vaccine ( OPV ) . Previous vaccination meningococcal serogroup A , C , W135 Y disease . Administration H. influenzae type b , diphtheria tetanus vaccine within 3 month first dose vaccine . For subject age 1214 month enrolment : For Austria : DTPaHBVIPV/Hib booster vaccination second year life : booster vaccine give Visit 2 . For Greece : DTPaIPV/Hib booster vaccination second year life : booster vaccine give Visit 2 . History meningococcal serogroup A , C , W135 Y disease . Known exposure meningococcal serogroup A , C , W135 Y disease within previous year . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>60 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Dose selection</keyword>
	<keyword>Toddlers</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Children</keyword>
</DOC>